See more : Finder Energy Holdings Limited (FDR.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Viveve Medical, Inc. (VIVE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Viveve Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- VMG Consumer Acquisition Corp. (VMGAU) Income Statement Analysis – Financial Results
- Xiangxing International Holding Limited (1732.HK) Income Statement Analysis – Financial Results
- Landcadia Holdings III, Inc (LCYAU) Income Statement Analysis – Financial Results
- Koninklijke KPN N.V. (KKPNF) Income Statement Analysis – Financial Results
- Canadian Pacific Railway Limited (CP) Income Statement Analysis – Financial Results
Viveve Medical, Inc. (VIVE)
About Viveve Medical, Inc.
Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.43M | 5.48M | 6.57M | 18.52M | 15.29M | 7.14M | 1.45M | 90.00K | 1.27M | 1.08M | 671.00K | 3.91M | 4.71M | 5.33M | 6.00M | 7.15M | 7.64M | 7.57M | 8.33M | 8.84M | 9.78M | 10.24M | 11.64M | 5.70M | 8.90M | 11.90M | 13.30M | 5.20M | 3.30M | 2.40M | 100.00K | 100.00K |
| Cost of Revenue | 5.81M | 5.18M | 5.55M | 11.20M | 7.84M | 4.61M | 985.00K | 50.00K | 531.00K | 541.00K | 426.00K | 1.38M | 2.10M | 2.20M | 2.64M | 2.73M | 3.07M | 3.07M | 3.34M | 4.09M | 5.59M | 3.29M | 3.30M | 1.40M | 3.30M | 2.90M | 4.00M | 2.50M | 2.70M | 1.90M | 0.00 | 0.00 |
| Gross Profit | 620.00K | 296.00K | 1.02M | 7.32M | 7.44M | 2.53M | 462.00K | 40.00K | 743.00K | 539.00K | 245.00K | 2.54M | 2.61M | 3.13M | 3.37M | 4.41M | 4.57M | 4.50M | 4.99M | 4.75M | 4.19M | 6.95M | 8.34M | 4.30M | 5.60M | 9.00M | 9.30M | 2.70M | 600.00K | 500.00K | 100.00K | 100.00K |
| Gross Profit Ratio | 9.65% | 5.40% | 15.47% | 39.53% | 48.69% | 35.42% | 31.93% | 44.44% | 58.32% | 49.91% | 36.51% | 64.83% | 55.47% | 58.72% | 56.11% | 61.77% | 59.85% | 59.47% | 59.89% | 53.70% | 42.83% | 67.85% | 71.66% | 75.44% | 62.92% | 75.63% | 69.92% | 51.92% | 18.18% | 20.83% | 100.00% | 100.00% |
| Research & Development | 9.67M | 5.13M | 8.59M | 13.72M | 12.34M | 8.37M | 4.99M | 1.43M | 2.12M | 2.03M | 1.21M | 333.00K | 780.00K | 2.08M | 2.38M | 1.92M | 2.75M | 2.13M | 980.00K | 889.00K | 904.00K | 1.68M | 2.67M | 4.50M | 5.20M | 2.80M | 0.00 | 2.20M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.51M | 13.67M | 22.36M | 38.57M | 28.83M | 12.87M | 7.46M | 4.28M | 3.33M | 2.63M | 2.45M | 2.81M | 3.46M | 3.16M | 3.79M | 3.01M | 3.34M | 3.33M | 3.30M | 3.63M | 7.44M | 9.43M | 10.05M | 13.70M | 13.00M | 7.00M | 7.30M | 3.00M | 4.50M | 3.60M | 1.90M | 100.00K |
| Other Expenses | 0.00 | -289.00K | -161.00K | 13.00K | 0.00 | 0.00 | 0.00 | 49.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.43M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.64M | 2.38M | 3.20M | 2.00M | 1.20M | 600.00K | 400.00K | 300.00K | 200.00K | 100.00K | 0.00 |
| Operating Expenses | 22.17M | 18.79M | 30.95M | 52.29M | 41.17M | 21.23M | 12.45M | 5.70M | 5.45M | 4.66M | 3.66M | 3.14M | 4.24M | 5.24M | 6.18M | 3.51M | 6.09M | 5.46M | 4.28M | 4.52M | 8.34M | 14.75M | 15.10M | 21.40M | 20.20M | 11.00M | 7.90M | 5.60M | 4.80M | 3.80M | 2.00M | 100.00K |
| Cost & Expenses | 27.98M | 23.97M | 36.50M | 63.48M | 49.02M | 25.85M | 13.44M | 5.75M | 5.98M | 5.21M | 4.08M | 4.51M | 6.34M | 7.44M | 8.81M | 6.24M | 9.15M | 8.53M | 7.62M | 8.61M | 13.93M | 18.04M | 18.40M | 22.80M | 23.50M | 13.90M | 11.90M | 8.10M | 7.50M | 5.70M | 2.00M | 100.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -80.00K | 10.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.00M | 910.00K | 4.35M | 4.37M | 3.17M | 1.37M | 415.00K | 567.00K | 337.00K | 555.00K | 396.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.14M | 1.30M | 1.18M | 786.00K | 449.00K | 111.00K | 77.00K | 56.00K | 53.00K | 43.00K | 9.00K | 42.00K | 96.00K | 145.00K | 109.00K | 118.00K | 140.00K | 122.00K | 122.00K | 211.00K | 904.00K | 3.64M | 2.38M | 3.20M | 2.00M | 1.20M | 600.00K | 400.00K | 300.00K | 200.00K | 100.00K | 0.00 |
| EBITDA | -19.63M | -18.50M | -30.68M | -44.17M | -33.34M | -18.63M | -11.93M | -5.66M | -4.65M | -4.08M | -3.31M | -3.07M | -1.53M | -1.96M | -2.70M | 908.00K | -1.38M | -833.00K | 714.00K | 231.00K | -3.50M | -4.16M | -4.39M | -13.90M | -12.56M | -800.00K | 2.00M | -2.50M | -3.90M | -3.10M | -1.80M | -100.00K |
| EBITDA Ratio | -305.51% | -342.84% | -440.32% | -242.83% | -220.24% | -261.92% | -828.61% | -6,174.44% | -365.07% | -377.96% | -493.74% | -16.85% | -32.60% | -38.71% | -52.03% | -11.78% | -21.27% | -13.31% | 12.40% | 4.16% | -35.79% | -44.48% | -39.52% | -252.63% | -143.82% | -10.92% | 10.53% | -55.77% | -127.27% | 904.17% | -1,400.00% | -100.00% |
| Operating Income | -21.55M | -18.50M | -29.94M | -44.97M | -33.73M | -18.70M | -11.99M | -5.66M | -4.70M | -4.13M | -3.41M | -603.00K | -1.63M | -2.11M | -2.81M | 908.00K | -1.52M | -955.00K | 714.00K | 231.00K | -4.15M | -7.80M | -6.77M | -17.10M | -14.60M | -2.00M | 1.40M | -2.90M | -4.20M | -3.30M | -1.90M | -100.00K |
| Operating Income Ratio | -335.40% | -337.56% | -455.87% | -242.83% | -220.63% | -261.92% | -828.61% | -6,291.11% | -369.23% | -381.94% | -508.49% | -15.42% | -34.58% | -39.57% | -46.75% | 12.71% | -19.85% | -12.61% | 8.57% | 2.61% | -42.46% | -76.20% | -58.15% | -300.00% | -164.04% | -16.81% | 10.53% | -55.77% | -127.27% | -137.50% | -1,900.00% | -100.00% |
| Total Other Income/Expenses | -218.00K | -3.04M | -11.22M | -4.36M | -3.23M | -1.41M | -436.00K | -518.00K | 8.20M | -4.26M | -3.58M | 98.00K | 3.00K | 99.00K | 426.00K | 436.00K | 248.00K | 175.00K | -197.00K | 74.00K | 251.00K | 393.00K | 211.00K | 500.00K | 159.00K | 500.00K | 700.00K | 400.00K | 300.00K | -24.80M | -400.00K | 0.00 |
| Income Before Tax | -21.77M | -21.53M | -41.90M | -49.32M | -36.96M | -20.11M | -12.43M | -6.18M | 3.50M | -8.39M | -6.99M | -505.00K | -1.63M | -2.01M | -2.38M | 1.34M | -1.27M | -780.00K | 517.00K | 305.00K | -3.90M | -7.41M | -6.56M | -16.60M | -14.40M | -1.50M | 2.10M | -2.50M | -3.90M | -28.10M | -2.30M | 0.00 |
| Income Before Tax Ratio | -338.80% | -392.99% | -638.02% | -266.37% | -241.75% | -281.63% | -858.74% | -6,866.67% | 274.65% | -776.57% | -1,041.73% | -12.92% | -34.51% | -37.71% | -39.66% | 18.81% | -16.61% | -10.30% | 6.20% | 3.45% | -39.90% | -72.36% | -56.33% | -291.23% | -161.80% | -12.61% | 15.79% | -48.08% | -118.18% | -1,170.83% | -2,300.00% | 0.00% |
| Income Tax Expense | 256.00K | -293.00K | 4.82M | -142.00K | -329.00K | 1.26M | 338.00K | 616.00K | 337.00K | 555.00K | -492.00K | -98.00K | -3.00K | -70.00K | -14.00K | 25.00K | -248.00K | 53.00K | 197.00K | -74.00K | -251.00K | -393.00K | -211.00K | -500.00K | -200.00K | -500.00K | 100.00K | -300.00K | -200.00K | 24.80M | 400.00K | 100.00K |
| Net Income | -22.03M | -21.24M | -46.72M | -49.18M | -36.63M | -20.11M | -12.43M | -6.18M | 3.50M | -8.39M | -5.76M | -505.00K | -1.63M | -1.94M | -2.37M | 1.32M | -1.27M | -833.00K | 517.00K | 305.00K | -3.90M | -7.41M | -6.56M | -16.60M | -14.40M | -1.50M | 2.00M | -2.60M | -4.00M | -28.10M | -2.30M | -100.00K |
| Net Income Ratio | -342.78% | -387.64% | -711.42% | -265.60% | -239.60% | -281.63% | -858.74% | -6,866.67% | 274.65% | -776.57% | -858.12% | -12.92% | -34.51% | -36.40% | -39.42% | 18.46% | -16.61% | -11.00% | 6.20% | 3.45% | -39.90% | -72.36% | -56.33% | -291.23% | -161.80% | -12.61% | 15.04% | -50.00% | -121.21% | -1,170.83% | -2,300.00% | -100.00% |
| EPS | -2.65 | -13.50 | -374.40 | -1.58K | -2.09K | -2.18K | -2.47K | -2.74K | 22.43K | -209.68K | -155.62K | -13.65K | -43.95K | -52.43K | -63.97K | 35.65K | -34.27K | -22.51K | 13.97K | 8.24K | -108.39K | -255.52K | -252.12K | -664.00K | -626.09K | -75.00K | 104.00K | -136.84K | -250.00K | -1.87M | -191.67K | -8.33K |
| EPS Diluted | -2.65 | -13.50 | -374.40 | -1.58K | -2.09K | -2.18K | -2.47K | -2.74K | 22.43K | -209.68K | -155.62K | -13.65K | -43.95K | -52.43K | -63.97K | 35.65K | -34.27K | -22.51K | 13.97K | 8.24K | -108.39K | -255.52K | -252.12K | -664.00K | -626.09K | -75.00K | 96.00K | -136.84K | -250.00K | -1.87M | -191.67K | -8.33K |
| Weighted Avg Shares Out | 10.09M | 1.57M | 124.78K | 31.06K | 17.50K | 9.22K | 5.02K | 2.25K | 156.00 | 40.00 | 37.00 | 37.00 | 37.00 | 37.00 | 37.00 | 37.00 | 37.00 | 37.00 | 37.00 | 37.00 | 36.00 | 29.00 | 26.00 | 25.00 | 23.00 | 20.00 | 19.00 | 19.00 | 16.00 | 15.00 | 12.00 | 12.00 |
| Weighted Avg Shares Out (Dil) | 10.09M | 1.57M | 124.78K | 31.06K | 17.50K | 9.22K | 5.02K | 2.25K | 156.00 | 40.00 | 37.00 | 37.00 | 37.00 | 37.00 | 37.00 | 37.00 | 37.00 | 37.00 | 37.00 | 37.00 | 36.00 | 29.00 | 26.00 | 25.00 | 23.00 | 20.00 | 19.00 | 19.00 | 16.00 | 15.00 | 12.00 | 12.00 |
Why Is Viveve Medical (VIVE) Stock Down 69% Today?
Viveve Medical (NASDAQ: VIVE ) stock is falling hard on Tuesday after releasing results from the company's latest clinical trial. That trial covers the use of the Viveve treatment for women suffering from stress urinary incontinence.
Viveve Medical, Inc. (VIVE) Q3 2022 Earnings Call Transcript
Viveve Medical, Inc. (NASDAQ:VIVE ) Q3 2022 Results Conference Call November 10, 2022 5:00 PM ET Company Participants Jeannie Swindle - Senior Director, Corporate Communications Scott Durbin - CEO Jim Robbins - SVP, Finance and Administration Operator Good afternoon. Welcome...
Viveve to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10, 2022
ENGLEWOOD, CO / ACCESSWIRE / October 27, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that it will report its third quarter 2022 financial...
Viveve Medical, Inc. (VIVE) CEO Scott Durbin on Q2 2022 Results - Earnings Call Transcript
Viveve Medical, Inc. (NASDAQ:VIVE ) Q2 2022 Earnings Conference Call August 11, 2022 5:00 PM ET Company Participants Jeannie Swindle - Senior Director, Corporate Communications Jim Robbins - SVP, Finance and Administration Scott Durbin - CEO Conference Call Participants Operator...
Viveve to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 11, 2022
ENGLEWOOD, CO / ACCESSWIRE / July 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that it will report its second quarter 2022 financial...
Viveve to Participate in H.C. Wainwright Global Investment Conference
ENGLEWOOD, CO / ACCESSWIRE / May 17, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright Global Investment Conference, May 23...
Viveve Medical, Inc. (VIVE) CEO Scott Durbin on Q1 2022 Results - Earnings Call Transcript
Viveve Medical, Inc. (NASDAQ:VIVE ) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Jeannie Swindle - Senior Director, Corporate Communications Jim Robbins - Senior Vice President, Finance and Administration Scott Durbin - Chief Executive Officer...
Viveve to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 12, 2022
ENGLEWOOD, CO / ACCESSWIRE / April 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its first quarter 2022 financial results and provide a corporate update after...
Viveve Medical Inc. (VIVE) CEO Scott Durbin on Q4 2021 Results - Earnings Call Transcript
Viveve Medical Inc. (VIVE) CEO Scott Durbin on Q4 2021 Results - Earnings Call Transcript
Viveve Medical, Inc. (VIVE) CEO Scott Durbin on Q3 2021 Results - Earnings Call Transcript
Viveve Medical, Inc. (VIVE) CEO Scott Durbin on Q3 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports